Biosplice Therapeutics Stock

biosplice.comHealthcare / BioTech & PharmaFounded: 2008

Biosplice Therapeutics is developing therapies through alternative pre-mRNA splicing, which can allow for the elimination of harmful proteins. The company's current pipeline focuses on osteoarthritis and oncology. Biosplice Therapeutics was founded in 2008 by Osman Kibar Ph.D., Dennis Carson, Richard Schwab, and John Hood Ph.D. and is headquartered in San Diego, CA.

Register for Details

For more details on financing and valuation for Biosplice Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Biosplice Therapeutics.

Register Today

Biosplice Therapeutics investors also invested in these private companies


Management Team

Cevdet Samikoglu
Chief Executive Officer & Board Member
Erich Horsley
Chief Financial Officer & Chief Business Officer
Scott Bulcao
Chief Legal Officer
Osman Kibar Ph.D
Co-Founder & Executive Chairman
Yusuf Yazici MD
Chief Medical Officer

Board Members

Chidozie Ugwumba
SymBiosis Capital Management
Gur Roshwalb MD
aMoon Fund
Joy Ghosh Ph.D
Eventide Asset Management
Kyle Rasbach Ph.D
Eventide Asset Management

Other companies like Biosplice Therapeutics in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Biosplice announces data from osteoarthritis clinical trial – and the initiation of new phase 3 trial
Biosplice Therapeutics, a clinical-stage biotech company pioneering first-in-class small molecule therapeutics, has announced potential structure-modifying highlights from an ongoing long-term extension study for its knee osteoarthritis (OA) drug candidate, lorecivivint.
The osteoarthritis market is expected to increase to $3.8bn in 2031
The osteoarthritis (OA) market was valued at $2.5 billion in the 7MM (seven major markets) in 2021, and is expected to increase to $3.8 billion in 2031, at a compound annual growth rate (CAGR) of 4.4%.
Updated on: Sep 21, 2023